CTXR has a worldwide license to develop Mino-Lok from the MD Anderson Cancer Center. It is a proprietary blend of three FDA approved compounds.
Late Stage Biotech Citius Pharma (NASDAQ: CTXR) Golden Cross Chart, Recent News and Phase III
Citius Pharma (NASDAQ: CTXR) FDA review data from the phase III trial of MIno-Lok may be a major catalyst for the company shares
Citius Pharmaceuticals (NASDAQ: CTXR) Positive Phase 3 Data, $1.5B Global Market, Trading Below Book, Full Research Report
The positive data from this analysis is a big milestone for Citius Pharma (NASDAQ: CTXR) and could act as a catalyst for the company’s shares.
